- Home
- INFY vs EW Comparison
INFY vs EW Comparison
Compare INFY & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INFY | EW |
|---|---|---|
| Founded | 1981 | 1958 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.9B | 50.2B |
| IPO Year | 1999 | 1999 |
Fundamental Metrics
Financial Performance| Metric | INFY | EW |
|---|---|---|
| Price | $13.19 | $82.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 21 |
| Target Price | $17.20 | ★ $96.47 |
| AVG Volume (30 Days) | ★ 15.4M | 3.9M |
| Earning Date | 04-16-2026 | 04-22-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $6,067,600,000.00 |
| Revenue This Year | N/A | $13.39 |
| Revenue Next Year | $7.49 | $9.78 |
| P/E Ratio | ★ $19.11 | $45.19 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $12.57 | $65.94 |
| 52 Week High | $30.00 | $87.89 |
Technical Indicators
Market Signals| Indicator | INFY | EW |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 47.88 |
| Support Level | $12.57 | $80.91 |
| Resistance Level | $17.56 | $82.64 |
| Average True Range (ATR) | 0.38 | 2.08 |
| MACD | 0.07 | -0.27 |
| Stochastic Oscillator | 31.82 | 28.89 |
Price Performance
Historical ComparisonAbout INFY Infosys Limited
Infosys is an IT services provider based in Bengaluru, India, with offices in more than 50 countries. The company leverages its offshore outsourcing model to serve clients across different industries, such as financial services and manufacturing. Infosys' IT services offerings include consulting, digital transformation, and business process outsourcing.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.